These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27999358)

  • 1. Review of Toxic Epidermal Necrolysis.
    Harris V; Jackson C; Cooper A
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of the Pathogenesis of Toxic Epidermal Necrolysis.
    Kinoshita Y; Saeki H
    J Nippon Med Sch; 2016; 83(6):216-222. PubMed ID: 28133001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidermal necrolysis: mechanisms of keratinocyte apoptosis].
    Roujeau JC; Gélard K; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):188-91. PubMed ID: 16457761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
    Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.
    Su SC; Chung WH
    Toxins (Basel); 2014 Jan; 6(1):194-210. PubMed ID: 24394640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
    Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Saeed HN; Chodosh J
    Semin Ophthalmol; 2016; 31(1-2):85-90. PubMed ID: 26959133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Noe MH; Micheletti RG
    Clin Dermatol; 2020; 38(6):607-612. PubMed ID: 33341195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the potential role of cytokines in toxic epidermal necrolysis.
    Nassif A; Moslehi H; Le Gouvello S; Bagot M; Lyonnet L; Michel L; Boumsell L; Bensussan A; Roujeau JC
    J Invest Dermatol; 2004 Nov; 123(5):850-5. PubMed ID: 15482470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Abe R
    J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis.
    de Araujo E; Dessirier V; Laprée G; Valeyrie-Allanore L; Ortonne N; Stathopoulos EN; Bagot M; Bensussan A; Mockenhaupt M; Roujeau JC; Tsapis A
    Exp Dermatol; 2011 Feb; 20(2):107-12. PubMed ID: 21255088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis.
    Schwartz RA; McDonough PH; Lee BW
    J Am Acad Dermatol; 2013 Aug; 69(2):173.e1-13; quiz 185-6. PubMed ID: 23866878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis.
    Viard-Leveugle I; Gaide O; Jankovic D; Feldmeyer L; Kerl K; Pickard C; Roques S; Friedmann PS; Contassot E; French LE
    J Invest Dermatol; 2013 Feb; 133(2):489-98. PubMed ID: 22992806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress in research of pathogeneses of Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Gao TT; Long Q
    Zhonghua Yan Ke Za Zhi; 2016 Sep; 52(9):708-13. PubMed ID: 27647252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?
    Paquet P; Piérard GE
    Dermatology; 1999; 198(2):198-202. PubMed ID: 10325481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic epidermal necrolysis: current evidence, practical management and future directions.
    Chave TA; Mortimer NJ; Sladden MJ; Hall AP; Hutchinson PE
    Br J Dermatol; 2005 Aug; 153(2):241-53. PubMed ID: 16086734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.